RT Journal Article
SR Electronic
T1 Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.04.22271911
DO 10.1101/2022.03.04.22271911
A1 Bosch, Guillermo
A1 Posso, Margarita
A1 Louro, Javier
A1 Roman, Marta
A1 Porta, Miquel
A1 Castells, Xavier
A1 Macià, Francesc
YR 2022
UL http://medrxiv.org/content/early/2022/03/07/2022.03.04.22271911.abstract
AB Background To assess the effect of the COVID-19 pandemic on performance indicators in the population-based breast cancer screening program of Parc de Salut Mar (PSMAR), Barcelona, Spain.Methods We conducted a before-and-after, quasi-experimental study to evaluate participation, recall, false-positives, cancer detection rate, and cancer characteristics in our screening population from March 2020 to March 2021 compared with the four previous rounds (2012-2019). Using independent logistic regression models, we estimated the adjusted odds ratios (aOR) of each of the performance indicators for the COVID-19 period, controlling by type of screening (prevalent or incident), socioeconomic index, family history of breast cancer, and menopausal status. We analyzed 144,779 observations from 47,571 women.Results During the COVID-19 period, the odds of participation were 11% lower in first-time invitees (aOR=0.89[95%CI=0.84-0.96]) and in those who had previously participated regularly and irregularly (aOR=0.65 [95%CI=0.61-0.69] and aOR=0.93 [95%CI=0.85-1.03], respectively). Participation showed a modest increase in women not attending any of the previous rounds (aOR=1.07 [95%CI=0.99-1.17]). The recall rate slightly decreased in both prevalent and incident screening (aOR=0.89 [95%CI=0.78-1.01] and aOR=0.89 [95%CI=0.79-1.00], respectively). No significant differences were observed in false-positives (prevalent - aOR=1.07 [95%CI=0.92-1.24] and incident screening -aOR=0.94 [95%CI=0.82-1.08]), cancer detection rate (aOR=0.91 [95%CI=0.69-1.18]), or cancer stages.Conclusions The COVID-19 pandemic negatively affected screening attendance, especially in previous participants and newcomers. We found no marked differences in recall, false-positives, or cancer detection, indicating the program’s resilience. There is a need for further evaluations of interval cancers and potential diagnostic delays.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has received funding by grants from Instituto de Salud Carlos III FEDER (grant numbers: PI19/00007 and PI21/00058), and by the Health Outcomes-Oriented Cooperative Research Networks (RICORS)), with reference RD21/0016/0020 co-funded with European Union - NextGenerationEU funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study guaranteed Spain's legal regulations on data confidentiality (law 15/99 of December 13 on the protection of personal data). Due to the retrospective nature of the study and the absence of direct contact with women, which did not affect their relationship with the program, informed consent was waived by the Ethics Committee of PSMAR, which approved the study (reg.2021/9866).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableSource data form all tables and figures can be found in the following Dataset: BOSCH, GUILLERMO, 2022, "Breast cancer screening program invitations (2012-2021)", https://doi.org/10.7910/DVN/VVQNWM, Harvard Dataverse, V1, UNF:6:CaW3sEp4tMsg13z2I1eZbQ== [fileUNF] Data from "Impact on covid19 dataset invited women.sav" was used in tables 1 and 2 and figures 1,2 and 3. Data from "cancer characteristics database.tab" was used in table 3.aORadjusted odds ratioBHAbasic Health AreaCIConfidence intervalPSMARParc de Salut Mar